

REMARKS

Claims 1 to 17 are pending in the subject application. By this Supplemental Amendment and Response, claim 10 has been amended to include matter that was inadvertently deleted from the claim in the Amendment filed December 9, 2002. The amendments to the claims are not intended to be a disclaimer or dedication to the public of the subject matter of the claims as previously presented. Support for the amendment is found in the application as filed, for example on page 6, the final paragraph and no new matter has been added. Entry of this amendment is respectfully requested.

CONCLUSION

For the reasons set forth above and in the Amendment and Response filed December 9, 2002, it is believed that all claims present in the application are in condition for allowance. Therefore, it is requested that this application be passed to allowance.

If an appropriate payment does not accompany or precede this submission, the Commissioner is hereby authorized to charge any fees required under 37 C.F.R. § § 1.16 and 1.17, including fees for any petition for extension of time, or credit any overpayment to Deposit Account No. 50-2518.

If the Examiner has any questions or would like to discuss this Amendment, please do not hesitate to contact the undersigned at the telephone number below.


Please address all correspondence regarding this communication to the following address:

Jennifer M. Phelps
Bingham McCutchen LLP
Three Embarcadero Center
San Francisco, California 94111
(213) 680-6400

Date: December 11, 2002

Respectfully submitted,

Bingham McCutchen LLP

By: 
Jennifer M. Phelps
Registration No. 48,656

Three Embarcadero Center
San Francisco, California 94111
Telephone: (213) 680-6459
Facsimile: (213) 680-6499

Version with Markings to Show Changes Made

1. (Amended) A method for ~~preventing~~prophylaxis or treating Sinusoidal Obstruction Syndrome ("SOS") comprising administering a matrix metalloproteinase ("MMP") inhibitor.
2. (Amended) A method for ~~preventing~~prophylaxis or treating chemotherapy- or radiation-induced liver disease comprising administering a matrix metalloproteinase ("MMP") inhibitor.
3. (Amended) The method of claim 2, wherein said chemotherapy-induced liver disease includes ~~SOS~~Sinusoidal Obstruction Syndrome, nodular regenerative hyperplasia, peliosis hepatis, immunosuppression-induced hepatic venoocclusive disease, and sinusoidal dilatation.
4. (Amended) The method of claims 1 or 2, wherein said MMPmatrix metalloproteinase inhibitor is ~~doxycycline~~doxycycline or 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid.
5. (Amended) The method of claim 4, wherein said MMPmatrix metalloproteinase inhibitor is ~~doxycycline~~doxycycline.
6. (Amended) The method of claim 5 wherein 15 mg/kg of said ~~doxycycline~~doxycycline is administered twice daily.
7. (Amended) The method of claim 4, wherein said MMPmatrix metalloproteinase inhibitor is 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid.
8. The method of claim 7 wherein 100-200 mg/hour of said 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid is administered.
9. (Amended) The method of claims 1 or 2 wherein said MMPmatrix metalloproteinase inhibitor is administered for up to 4 weeks.
10. (Twice Amended) The method of claims 1 or 2, wherein said MMPmatrix metalloproteinase inhibitor is Marimastat, Prinomastat, RS-130,830, CGS-27023A(N-hydroxy-2(R)-[[4-methoxysulfonyl](3-picolyl) amino]-3-methylbutamide hydrochloride monohydrate, Solimastat, BAY 12-9566, Re(3(R)(cyclopentylmethyl)-2(R)-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-4-oxo-4-piperidinobutyrohydroxamic 32-3555,acid), BMS-272591, Ilomastat, D2163, Metastat, Neovastat, or Periostat.

Version with Markings to Show Changes Made

11. (Amended) A method for ~~preventing~~prophylaxis or treating chemotherapy or radiation induced liver disease comprising administering an effective dose of a matrix metalloproteinase ("~~MMP~~") inhibitor selected from ~~doxycycline~~doxycycline or 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid.
12. (Amended) The method of claim 11, wherein said ~~MMP~~matrix metalloproteinase inhibitor is ~~doxycycline~~doxycycline.
13. (Amended) The method of claim 12, wherein 15 mg/kg of said ~~doxycycline~~doxycycline is administered twice daily.
14. (Amended) The method of claim 11, wherein said ~~MMP~~matrix metalloproteinase inhibitor is 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid.
15. The method of claim 14, wherein 100-200 mg/hour of said 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid is administered.
16. (Amended) A method for ~~preventing~~prophylaxis or treating chemotherapy or radiation induced liver disease comprising administering 15 mg/kg of ~~doxycycline~~doxycycline twice daily.
17. (Amended) A method for ~~preventing~~prophylaxis or treating chemotherapy or radiation induced liver disease comprising administering 100-200 mg/hour of 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid.